Checkpoint ligand expression in non-tumoral cells of tissues affected by immune-related adverse effects has been described in ICI-associated hypophysitis, myocarditis, and acute interstitial nephritis. We aimed to investigate the tissue expression of the immune checkpoint receptor programmed cell death-1 ...
Programmed death ligand 1 (PD-L1) found on tumor cells has recently been reported to have a key role in the development and dissemination of many tumors, such as lung and breast carcinomas. In this study, we retrospectively analyzed PD-L1 expression among different types of sarcomas.Tissue mi...
Lantheus Holdings, Inc. recently announced the first patient has been dosed in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells, for its potential to identify pa...
PD-L1 expression on circulating tumor cells (CTCs) could aid in screening and monitoring patients16. CTCs are tumor cells that are shed from various locations of the primary and/or metastatic tumors17,18,19. As such, they may represent a greater portion...
Indeed an increased expression of PD-L1 by both cancer and intra-tumoral immune cells is associated with an increased likelihood of response to anti-PD-1/PD-L1-based immunotherapy [26, 27, 30, 32]. Nevertheless, not all high PD-L1 positive tumors respond to the treatment while some PD-...
[12] Faraj SF, Munari E, Guner G, et al. Assessment of tumoral PD- L1 expression and intratumoral CD8 + T cells in urothelial carcinoma[J]. Urology, 2015, 85(3): 703.e1-6. DOI:10.1016/j.urology.2014.10.020...
Ovarian clear cell carcinoma (OCCC), well known for its chemoresistance to platinum-based chemotherapy, exhibited a good response in clinical trials of anti–PD-1/PD-L1 inhibitors. By assessing PD-L1 expression, we sought to determine the potential therapeutic benefit of PD-1/PD-L1 inhibitors ...
PD-L1 expression in TILs and tumor cells were assessed in all 111 patients. The strongest PD-L1 expression of the three cores of each case was used for further statistical analyses. Results in ovarian tissue did not correlate with peritoneal metastases. PD-L1 expression in tumor cells in ovari...
Further, THZ1 suppressed PD-L1 expression by inhibiting MYC activity. THZ1 boosted antitumor immunity by recruiting infiltrating CD8+ T cells and synergized with antiPD-1 therapy. The CDK7/MYC/PD-L1 signature and infiltrating T cell status collectively stratified NSCLC patients into different risk ...
cells. Here, we show that exosomes derived from lung cancer cells express PD-L1 and play a role in immune escape by reducing T-cell activity and promoting tumor growth. The abundance of PD-L1 on exosomes represented the quantity of PD-L1 expression on cell surfaces. Exosomes containing PD-...